- Molecular Diagnostic/Genomic Services
In 2006, the Company transferred to bioMerieux a diagnostic panel for the screening of breast cancers in blood. The Company will now continue the projects which have been initiated in common in 2006 and 2007, i.e., blood diagnostic of colon cancer and blood diagnostic of prostate cancer.
In house diagnostic research will also continue for Alzheimer's disease in order to identify, at an early stage, individuals who can develop Alzheimer's disease, and in order to service the existing test to assist the pharmaceutical industry in recruiting homogeneous cohort of patients for clinical trials for new drugs.
In genomic services, the Company, in collaboration with renowned scientists, intends to continue researches on different pathologies to increase the penetration of its new generation of tools, the SpliceArray(TM), in the scientific and medical communities. New biochips, particularly on the Agilent platform, will contribute to fuel the growth of this activity.
The strategic collaboration with Allergan will continue with the ambition to validate new pharmacologic programs for clinical trials in man.
In house, Phase 2 study will be realized with EHT0202, in several clinical sites, on 135 patients suffering from Alzheimer's disease, randomized in double-blind. The main objective is to determine the tolerability and safety of the product in an oral administration over a 3 month period, in association with inhibitors of acetylcholinesterase, which is the usual treatment for this disease. The study will also allow the collection of preliminary data on the clinical efficacy of the product, notably on a cognitive and behavioural standpoint.
2007 Consolidated financials results
- Income Statement
Consolidated R&D revenues were EUR 5.3 million in 2007, down 5%
compared to EUR 5.6 million in 2006. Total revenues amou
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved